Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results

Journal of Medical Investigation

Volumn 55, Issue 1-2, 2008, Pages 54-60

  Honda, Junko ^a   Sasa, Mitsunori ^b   Moriya, Takuya ^c   Bando, Yoshimi ^a   Hirose, Toshiyuki ^d   Takahashi, Masako ^b   Nagao, Taeko ^a   Tangoku, Akira ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Tokushima Breast Care Clinic   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d National Hospital Organization   (Japan)

Author keywords

Breast cancer; Capecitabine; Dihydropyrimidine dehydrogenase; Predictive factor; Thymidine phosphorylase

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; HORMONE; THYMIDINE PHOSPHORYLASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CASE REPORT; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; PROTEIN EXPRESSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; FORECASTING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RETROSPECTIVE STUDIES; THERAPEUTIC EQUIVALENCY; THYMIDINE PHOSPHORYLASE; TREATMENT OUTCOME;

EID: 43149114411     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.55.54     Document Type: Article

References (23)

1. Early Breast Cancer Trialists' Collaborative Group : Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of randomized trials. Lancet 365 : 1687-1717, 2005
2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ : Meeting highlights : international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (in press).
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L : Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 : 783-792, 2001
4. Pritchard KL, Shepherd LE, O'Malley FP, Andrulis IL,TuD, Bramwell VH, Levine MN : HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354 : 2103-2111, 2006
5. Tominaga T, Toi M, Ohashi Y, Abe O : Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer. Clin Breast Cancer 3 : 55-64, 2002
6. Tominaga T, Toi M, Abe O, Ohashi Y, Uchino J, Hayasaka H, Abe R, Izuo M, Enomoto K, Watanabe H, Yoshida M, Taguchi T, Koyama H, Senoo T, Toge T, Monden Y, Hattori T, Nomura Y, Sugimachi K, Hirata K, Nakazato H, Miura S, Morimoto T, Asaishi K, Kimijima I, Ota J, Sonoo H, Yamaguchi S : The effect of adjyvant 5′-deoxy-5-fluorouridine in early breast cancer patients : results from a multicenter randomized controlled trial. Int J Oncol 20 : 517-525, 2002
7. Kurosumi M, Sugawara N, Tabei T, Inoue K, Matsumoto H, Suematsu K, Higashi Y : Comparison of ELISA level and immunohistochemical status for thymidine phosphorylase (TP) in invasive breast carcinoma. Anticancer Res 22 : 331-338, 2002
8. Kurosumi M : Significance of immunohistochemical evaluation of TS, DPD and TP expression as predictive factors of treatment effect in breast cancer. Jpn J Breast Cancer 18 : 419-427, 2003
9. th Edition), Kanehara, Tokyo, 2005, pp.1-27
10. Massacesi C, La Cesa A, Marcucci F, Pilone A, Rocchi M BL, Zepponi L, Santini D, Tonini G, Burattini, L : Capecitabine and mitomycin C is an effective combination for anthracycline-and taxan-resistant metastatic breast cancer. Oncology 70 : 294-300, 2006
11. Sawada N, Ishikawa T, Fukase Yu, Nishida M, Yoshikubo T, Ishitsuka H : Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4 : 1013-1019, 1998
12. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H : Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58 : 685-690, 1998
13. Yamamoto Y, Toi M, Tominaga T : Prediction of effect of 5′-deoxy-5-fluorouridine by the status of angiogenetic enzyme thymidine phosphorylase expression in recurrent breast cancer patients. Oncol Reports 3 : 863-865, 1996
14. Kakimoto M, Uetake H, Osanai T, Shirota Y, Takagi Y, Takeshita E, Toriya Y, Danenberg K, Danenberg PV, Sugihara K : Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Letters 223 : 103-111, 2005
15. Jakob C, Liersch T, Meyer W, Baretton GB, Hausier P, Schwabe W, Becker H, Aust DE : Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III) Correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemotherapy. Am J Surg Patho 29 : 1304-1309, 2005
16. Yamaue H, Tanimura H, Kono N, Aoki Y, Tabuse K, Uchiyama K, Takifuji K, Iwahashi M, Tani M : Clinical efficacy of doxifluridine and correlation to in vitro sensitivity of anticancer drugs in patients with colorectal cancer. Anticancer Res 23 : 2559-2564, 2003
17. Toi M, Bando H, Horiguchi S, Takada M, Kataoka A, Ueno T, Saji S, Muta M, Funata N, Ohno S : Modulation of thymidine phophorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 90 : 2338-2343, 2004
18. Popat S, Matakidou A, Houlston RS : Thymidylate synthase expression and prognosis in colorectal cancer : a systematic review and meta-analysis. J Clin Oncol 22 : 529-536, 2004
19. Nishimura G, Terada I, Kobayashi T, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Kayahara M, Shimizu K, Ohta T, Miwa K : Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Reports 9 : 479-482, 2002
20. Hu YC, Komorowski RA, Graewin S Hostetter G, Kollioniemi OP, Pitt HA, Ahrendt SA: Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res 9 : 4165-4171, 2003
21. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johston PG, Magnusson I, Ragnhammar P, Blomgen H : Thymidylate synthase expression in colorectal cancer : A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20 : 1721-1728, 2002
22. Leichman CG : Thymidylate synthase as a predictor of response. Oncology 12 : 43-47, 1998
23. Magne N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, Tiffon C, Renee N, Marchetti S, Etienne MC, Malano G : ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity : rational basis for a new combination therapy with capecitabine. Clin Cancer Res 9 : 4735-4742, 2003